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Candida guilliermondii is a common species isolated both
from clinical specimens and the environment. Human infec-
tions caused by C. guilliermondii are uncommon particularly
in immunocompetent individuals.1 Molecular typing methods
have helped to characterize the strains of C. guilliermondii
into different groups, one of which has been named as
Candida fermentati.2 This species includes organisms phe-
notypically similar to C. guilliermondii but with minimal
nucleotide divergence in the D1/D2 domains of 26S rDNA.3
This is the first report of the isolation of C. fermentati from
the oral cavities of HIV patients.
C. fermentati was isolated from five HIV patients, four
of whom had oral lesions, while one was asymptomatic.
Only one patient had a CD4 cell count below 50 cells/mm3
(Table 1). The isolates were initially speciated by sugar
fermentation and assimilation tests. Susceptibility to azole
antifungals fluconazole and itraconazole was tested by
determination of minimum inhibitory concentrations
(MIC) using the agar dilution method according to Troke
and Pye.4
The isolates resembled C. guilliermondii by sugar fermen-
tation and assimilation tests, but differed from C. guillier-
mondii in their inability to assimilate glycerol. They were
confirmed to be C. fermentati by Dr Wieland Meyer, Uni-
versity of Sydney at the Westmead Millennium Institute,
Australia, by PCR fingerprinting, and the primer used was
50 GAGGGTGGCGGTTCT 30 from the core sequences of wild
type phage M13.5 All the five isolates showed PCR fingerprint-Table 1 Patient profile and antifungal susceptibility of Candida
Patient No. Age/sex Specimens
collected
Oral lesions MIC
(mg/
Fluc
1 61/M Oral swab + 4 (S)
2 29/M Mouthwash + 64 (R
3 38/M Mouthwash + 2 (S)
4 28/M Mouthwash + 16 (S
5 29/F Mouthwash  4 (S)
MIC, minimum inhibitory concentration; S, sensitive; R, resistant; SDD
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doi:10.1016/j.ijid.2008.04.007ing profiles that were identical to the standard strains of C.
fermentati CBS 2022. Four of the five isolates were sensitive
to itraconazole, whereas one showed reduced sensitivity.
Two of the five patients were on fluconazole prophylaxis,
and isolates from these patients were either resistant or
showed reduced susceptibility to fluconazole (Table 1). Oral
lesions resolved in all the patients with azole therapy, but
none of them could be followed up for recurrences.
This is the first report of C. fermentati as the causative
agent of oral candidiasis. The organism is difficult to differ-
entiate from C. guilliermondii phenotypically, and the cri-
teria used for differentiation are the delayed fermentation of
D-galactose and assimilation of glycerol.6 Our study showed
that both C. guilliermondii as well as C. fermentati fermen-
ted D-galactose at 30 8C and hence this may not be an
important differentiating character. Other workers have
made similar observations.3
San Millan et al. have used randomly amplified poly-
morphic DNA (RAPD) and isoenzyme analysis for differentia-
tion of a set of C. guilliermondii isolates and found some of
them to be C. fermentati. However there have been no
previous reports of C. fermentati as an etiological agent
of disease. PCR fingerprinting using M13 primers, which
has been used previously to differentiate between strains
of Candida albicans and Candida dubliniensis,5 has been used
here to differentiate between C. fermentati and C. guillier-
mondii. Yeasts with similar phenotypic characteristics have
always posed a problem to taxonomists, and genotypic char-
acteristics are valuable in discriminating between such
organisms.
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determination
ml)
CD4 cell counts
(cells/mm3)
Fluconazole
prophylaxis
onazole Itraconazole
0.25 (SDD) 406 No
) 0.125 (S) 350 Yes
0.125 (S) 46 No
DD) 0.062 (S) ND Yes
0.062 (S) ND No
, susceptible dose-dependent; ND, not done.
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